All episodes of The Biotech Startups Podcast

Episodes

🧬 Bryan Dechairo - Sherlock Biosciences - Part 3 | Assurex’s Journey From Garage to GeneSight | Keeping a Team Together Through the M&A Process | Building a Diagnostics Company During Covid | What Sherlock & Netflix Have in Common

Part 3 of 3. My guest for this week’s episode is Bryan Dechairo, President, CEO, and Director at Sherlock Biosciences, an innovative biotech company that is enabling the democratization and decentralization of diagnostic testing to personalize healthcare and make an impact on global health.

Published 05/08/24

The Biotech Startups Podcast

Published 05/08/24

🧬 Bryan Dechairo - Sherlock Biosciences - Part 2 | Transitioning From a Small Startup to Pfizer | Big Data's Role in Modern Genetics | Building & Leading Dynamic Teams | The Evolution of Personalized Medicine

Part 2 of 3. My guest for this week’s episode is Bryan Dechairo, President, CEO, and Director at Sherlock Biosciences, an innovative biotech company that is enabling the democratization and decentralization of diagnostic testing to personalize healthcare and make an impact on global health.

Published 05/01/24

🧬 Bryan Dechairo - Sherlock Biosciences - Part 1 | A Love of Science Blossoming from a 10-Acre Hobby Farm | Experiencing Great Diversity at UC Berkeley | Growth & Enjoyment of Startups | Unexpected Travels to Pursue a Dream Overseas

Part 1 of 3. My guest for this week’s episode is Bryan Dechairo, President, CEO, and Director at Sherlock Biosciences, an innovative biotech company that is enabling the democratization and decentralization of diagnostic testing to personalize healthcare and make an impact on global health. The Sherlock team and founders include engineering biology pioneers with world-leading expertise in CRISPR and synthetic biology, diagnostic industry veterans, and disease area authorities.

Published 04/24/24

🧬 Terry Lo - Vizgen - Part 3 | Transitioning to Vizgen From Akoya | What is Spatial Genomics | The Importance of Genetic Mapping | How to Grow Your Company During Turbulent Times

Part 3 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics. Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of...

Published 04/17/24

🧬 Terry Lo - Vizgen - Part 2 | Terry’s Move from Big Pharma to Diagnostics | Introduction to Spatial Biology | Navigating Regulatory & Reimbursement Challenges in Diagnostics | Balancing Multiple Roles in M&A Negotiations

Part 2 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomic. Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of...

Published 04/10/24

🧬 Terry Lo - Vizgen - Part 1 | Leveraging Passion for Science to Succeed in Finance | Sales Excellence as an Introvert Through Competition | Financial Modeling & Creating Proper Deal Structure | How Not To Be A Jack of All Trades

Part 1 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics. Vizgen’s technology will aid the acceleration of biological research and discovery to advance human health

Published 04/03/24

🧬 Mike Stadnisky - Thielsen Capital - Part 3 | Don’t Fake it ‘Til you Make It | Cleaning Your Corporate “Underwear” | Thielsen’s Investment Philosophy | The Critical Importance of Alignment

Part 3 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science.

Published 03/27/24

🧬 Mike Stadnisky - Thielsen Capital - Part 2 | Transitioning from Academia to Business | Breaking Into Business Development | Finding Decision Makers & Champions | Navigating Partnerships & Strategy

Part 2 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science. Before Thielsen, Mike was the CEO of Phitonex, which Thermo Fisher acquired. He was also VP & GM of Informatics at BD Life Sciences and was the CEO of FlowJo before its acquisition by...

Published 03/20/24

🧬 Mike Stadnisky - Thielsen Capital - Part 1 | Familial Exposure to Business & Science at a Young Age | The Importance of “Care Before You Share” | Actively Managing Your Time | A PhD is a 10,000 Hour Degree

Part 1 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science. Before Thielsen, Mike was the CEO of Phitonex, which Thermo Fisher acquired. He was also VP & GM of Informatics at BD Life Sciences and was the CEO of FlowJo before its acquisition by...

Published 03/13/24

🧬 Martin Brenner - iBio - Part 3 | Transitioning from Big Pharma to Biotech Startups | Lessons in Flexibility, Resilience, & Adaptability | Challenging Long-Held Beliefs in Drug Discovery | The Evolution & Future of iBio

Part 3 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.

Published 03/06/24

🧬 Martin Brenner - iBio - Part 2 | Autonomy at Eli Lilly vs. Structure at Pfizer | Transitioning from AstraZeneca to Merck | Joys & Challenges When Relocating for Work | A Biotech Vision Leading to an Exit From Big Pharma

Part 2 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.

Published 02/28/24

🧬 Martin Brenner - iBio - Part 1 | How Childhood Influences Shape Career Paths | Unexpected Crossovers Between Engineering & Veterinary Clinics | Eli Lilly Nurturing His Professional Development | Communication Can Make or Break Leadership

Part 1 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.

Published 02/21/24

🧬 Jeff Kim - Slingshot Biosciences - Part 3 | Bucking the Status Quo | Raising Capital During Peak COVID | How To Find & Retain Great Talent | Building Partnerships with Distributors

Part 3 of 3. My guest for this week’s episode is Jeff Kim, co-founder and CEO of Slingshot Biosciences. Slingshot designs and manufactures synthetic cells for R&D, clinical diagnostics, and engineered cell therapies, aiming to overcome supply chain and cost barriers that restrict access to advanced diagnostics and therapeutics.

Published 02/14/24

🧬 Jeff Kim - Slingshot Biosciences - Part 2 | Working Toward One Goal In Industry | How Great Loss Prompted Professional Growth | Transitioning From a Basement Lab to a Thriving Company | A 6-Month Startup Idea Exceeding 12 Years of Operation

Part 2 of 3. My guest for this week’s episode is Jeff Kim, co-founder and CEO of Slingshot Biosciences. Slingshot designs and manufactures synthetic cells for R&D, clinical diagnostics, and engineered cell therapies, aiming to overcome supply chain and cost barriers that restrict access to advanced diagnostics and therapeutics.

Published 02/07/24

🧬 Jeff Kim - Slingshot Biosciences - Part 1 | Parental Freedom, Curiosity, & Self-Teaching | Music Accentuating a Passion for Science | The Benefits of Graduate Responsibilities as an Undergrad | Finding Fit & Balancing Research & the Arts

My guest for this week’s episode is Jeff Kim, co-founder and CEO of Slingshot Biosciences. Slingshot designs and manufactures synthetic cells for R&D, clinical diagnostics, and engineered cell therapies, aiming to overcome supply chain and cost barriers that restrict access to advanced diagnostics and therapeutics.

Published 01/31/24

Part 3 of 3. My guest for this week’s episode is Stephanie Sirota, Partner, and Chief Business Officer at RTW Investments, a full lifecycle life sciences investment firm dedicated to solving the most challenging unmet patient needs. Stephanie is a seasoned expert and leader in business development, strategic partnerships, communications, and investor relations.

Published 01/24/24

🧬 Stephanie Sirota - RTW Investments - Part 2 | Understanding Investment Banking’s Role in the Biosciences | Finding the Benefits of Your Uniqueness | Unexpected Pivots & Finding Passion in Your Work | Advice on Dealing with Bear Markets

Part 2 of 3. My guest for this week’s episode is Stephanie Sirota, Partner, and Chief Business Officer at RTW Investments, a full lifecycle life sciences investment firm dedicated to solving the most challenging unmet patient needs. Stephanie is a seasoned expert and leader in business development, strategic partnerships, communications, and investor relations.

Published 01/17/24

Part 1 of 3. My guest for this week’s episode is Stephanie Sirota, Partner, and Chief Business Officer at RTW Investments, a full lifecycle life sciences investment firm dedicated to solving the most challenging unmet patient needs. Stephanie is a seasoned expert and leader in business development, strategic partnerships, communications, and investor relations.

Published 01/10/24

Part 3 of 3. My guest for this week’s episode is Kittu Kolluri, Founder and Managing Director of Neotribe Ventures, an early- and growth-stage venture capital firm investing in companies that solve hard technical problems and disrupt non-traditional industry sectors.

Published 01/03/24

🧬 Kittu Kolluri - Neotribe Ventures - Part 2 | The Importance of Co-Authoring a Culture Statement | The Difference Between Leadership & Management | Raising Funds in Down-Market Conditions | The Value of Authenticity & Intellectual Curiosity

Part 2 of 3. My guest for this week’s episode is Kittu Kolluri, Founder and Managing Director of Neotribe Ventures, an early- and growth-stage venture capital firm investing in companies that solve hard technical problems and disrupt non-traditional industry sectors.

Published 12/20/23

🧬 Kittu Kolluri - Neotribe Ventures - Part 1 | Entrepreneurship as a First-Generation Immigrant | Working & Growing at Silicon Graphics | Learning From Mistakes & Pride of Ownership | The Dangers of Company Microcultures

Part 1 of 3. My guest for this week’s episode is Kittu Kolluri, Founder and Managing Director of Neotribe Ventures, an early- and growth-stage venture capital firm investing in companies that solve hard technical problems and disrupt non-traditional industry sectors. Neotribe is led by a team of serial entrepreneurs with a track record of supporting and advising startups from seed round to IPO.

Published 12/13/23

🧬 Fengru Lin - TurtleTree - Part 3 | The Value of Early HR for Company Building | Creating a People-First Work Culture | Refocusing to Reach Commercialization Sooner | Navigating Seed Series Fundraising

Part 3 of 3. My guest for this week’s episode is Fengru Lin, Founder and CEO of TurtleTree, a biotech company revolutionizing food for good. Having raised a 40 million dollar Series A, TurtleTree is creating cell-based milk, with a current focus on releasing LF+, the world’s first sustainably produced lactoferrin made with cutting-edge precision fermentation technology.

Published 12/06/23

🧬 Fengru Lin - TurtleTree - Part 2 | Salesforce’s Customer-Centric Sales Motion | The Value of Knowing Your Audience in Every Conversation | Why Executive Buy-In Matters | How a Hobby Led to TurtleTree’s Founding Idea

Part 2 of 3. My guest for this week’s episode is Fengru Lin, Founder and CEO of TurtleTree, a biotech company revolutionizing food for good. Having raised a 40 million dollar Series A, TurtleTree is creating cell-based milk, with a current focus on releasing LF+, the world’s first sustainably produced lactoferrin made with cutting-edge precision fermentation technology.

Published 11/29/23

Part 1 of 3. My guest for this week’s episode is Fengru Lin, Founder and CEO of TurtleTree, a biotech company revolutionizing food for good. Having raised a 40 million dollar Series A, TurtleTree is creating cell-based milk, with a current focus on releasing LF+, the world’s first sustainably produced lactoferrin made with cutting-edge precision fermentation technology. Prior to TurtleTree, Fengru worked at UL, Salesforce, and Google, gaining a tremendous amount of experience in sales and...

Published 11/22/23